VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

The companies entered into an arbitration agreement that resolves three lawsuits related to their 1994 collaboration on an encapsulated cell therapy to treat diabetes (see BioCentury, June 1). Under the settlement, Mylan accepted title to an office building owned by VivoRx, and VivoRx has leased back the facility for four years from Mylan with an option to repurchase the building. VivoRx also may repurchase its stock from Mylan for $15 million within five years. ...